Parkinson's Disease Therapeutics Flashcards
Stages of Disease
Stage 1 (unilateral; symptoms not disabling; tremor in one limb but no posture or facial expression changes)
Stage 2 (bilateral; slowed speech, decreased posture and abnormal gait; no balance impairment)
Stage 3 (Worsening; significant posture and balance problems; bradykinesia; mild to moderate disability)
Stage 4 (rigidity and bradykinesia; needs walking assistance; unable to live alone; severe disability)
Stage 5 (Unable to stand or walk; constant care)
Somatic Non-motor symptoms of PD
Sweating, hypotension, constipation, overactive bladder, seborrheic dermatitis, soft voice, decreased facial expression, decreased on arm swing (first side involved), decreased sense of smell and rapid eye movement disorder
Behavioral PD symptoms
Depression, anxiety, psychosis (visual hallucinations usually pleasant; delusions/paranoia), dementia (increased risk because of hallucinations)
Parkinson’s Medications provide control for _________ years
4-6
In PD, health related quality of life is largely determined by ______________________
non-motor features
Factors contributing to rapid progression of PD
Older age at onset, male with initial gate difficulty/postural instability, decreased response to L-DOPA, psychosis
Factors contributing to milder PD progression
Tremor only major sign at initial diagnoses, good response to L-DOPA
Essential tremor vs PD
In essential tremor, tremor is only symptom (PD presents with rigidity, tremor, balance, falling, slowness of movement, etc.)
In essential tremor, tremor occurs when hands are in use (resting tremor in PD)
In essential tremor, hands, head and voice impacted (no head or voice in PD)
In essential tremor, alcohol reduces tremor (no effect in PD)
Pharmacologic options for PD
Dopamine precursor (L-DOPA - carbidopa; Sinemet CR)
1st Generation Dopamine Agonists (Bromocriptine, Apomorphine)
2nd Gen (Pramipexole, Ropinerole, Rotigotine Patch)
MAO-B Inhibitors (Selegiline, Rasagiline)
COMT Inhibitors (Tolcapone, Entacapone)
Antiviral NMDA (Amantadine)
Anticholinergics (Benztropine, Trihexyphenidyl)
Levodopa/Carbidopa
First line (wait until symptoms are disabling)
Greatest benefit with fewest ADE in short term (most effective for bradykinesia then tremor and rigidity; not effective for instability or freezing)
TID to QID; titrated q 3 day then switch to CR BID-QID
Best use in stage 2-5 or as initial treatment in older person
Levodopa-Carbidopa Side Effects
Nausea, insomnia, akathisia, dyskinesias, confusion, elevated liver enzymes, postural hypotension, visual hallucinations
On-off phenomenon (freezing off period to dyskinetic movement on period) –> unrelated to dose time, sign of becoming refractory
L-DOPA Induced Dyskinesia
Occurs afte 5-6 years or early in therapy (6 months) if high doses are used initially
Off-period dystonia (painful feet spasms when LDOPA levels are low)
Diphasic dyskinesia (occurs when levels are rising or falling; rigidity or involuntary movement with muscles of lower limbs)
Peak-Dose dyskinesia (most common form; correlates with peak plateau plasma levels and impacts upper limbs, head, trunk and respiratory muscles)
Treatment for L-DOPA Side Effects
End of dose wearing off (increase frequency or change to CR; add COMT or MAO inhibitor; dopamine agonist)
Delayed onset (take on empty stomach, use ODT or IR form; avoid taking with high protein food/drink; crush tablet and take with water only)
Start hesitation/Freezing (increase dose; add DA or MAO-B inhibitor; Physical therapy)
Peak Dose Dyskinesia (use smaller doses more frequently; add amantadine)
Lillipuition hallucinations
PD see tiny people (could be medication OR disease related)
Major contributors for psychosis/hallucinations in PD
Amantadine, COMT inhibitors, dopamine agonists, levodopa
Anticholinergic medications (oxybutynin, tolterodine, benzotropine, diphenhydramine)